Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 6 institutions in 2 countries.
Sophia S BorisevichUfa Institute of Chemistry, Ufa Federal Research Center of the Russian Academy of Sciences, Ufa 450054, Russia.ORCID 0000-0001-8481-0470
Tatiana E AksininaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.ORCID 0000-0002-6770-2328
Margarita G IlyinaUfa Institute of Chemistry, Ufa Federal Research Center of the Russian Academy of Sciences, Ufa 450054, Russia.ORCID 0000-0002-5552-9353
Victoria O ShenderShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.
Ksenia S AnufrievaLopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of the Federal Medical and Biological Agency, Moscow 119435, Russia.
Georgij P ArapidiShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.ORCID 0000-0003-2323-1859
Nadezhda V AntipovaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.
Fabrice AnizonUniversité Clermont Auvergne, Centre National de la Recherche Scientifique, Clermont Auvergne Institut National Polytechnique, Institute of Chemistry of Clermont-Ferrand, F-63000 Clermont-Ferrand, France.
Yannick J EsvanUniversité Clermont Auvergne, Centre National de la Recherche Scientifique, Clermont Auvergne Institut National Polytechnique, Institute of Chemistry of Clermont-Ferrand, F-63000 Clermont-Ferrand, France.
Francis GiraudUniversité Clermont Auvergne, Centre National de la Recherche Scientifique, Clermont Auvergne Institut National Polytechnique, Institute of Chemistry of Clermont-Ferrand, F-63000 Clermont-Ferrand, France.ORCID 0000-0001-7600-3687
Victor V TatarskiyInstitute of Gene Biology, Russian Academy of Sciences, Moscow 119334, Russia.ORCID 0000-0002-9080-5683
Pascale MoreauUniversité Clermont Auvergne, Centre National de la Recherche Scientifique, Clermont Auvergne Institut National Polytechnique, Institute of Chemistry of Clermont-Ferrand, F-63000 Clermont-Ferrand, France.ORCID 0000-0001-6527-7586
Mikhail I ShakhparonovShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.
Marat S PavlyukovShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.
Alexander A ShtilBlokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
Institute of Bioorganic Chemistry · RUUniversité Clermont Auvergne · FRUfa Institute of Chemistry · RUFederal Medical-Biological Agency · RUInstitute of Gene Biology · RULomonosov Moscow State University · RU
Funding
Program 'Molecular and cellular mechanisms of oncological, immune and metabolic diseases, modeling and experimental investiga-tion of reprogramming and cancer targeting' 075-15-2020-773
6 · The paper itself
Abstract
Serine-threonine protein kinases of the DYRK and CLK families regulate a variety of vital cellular functions. In particular, these enzymes phosphorylate proteins involved in pre-mRNA splicing. Targeting splicing with pharmacological DYRK/CLK inhibitors emerged as a promising anticancer strategy. Investigation of the pyrido[3,4-
Indexed as
antitumor drug designCLK protein kinasesDYRK protein kinasesgene transcriptionglioblastomapyridoquinazolinesquantum chemical calculationsRNA splicing
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Nitro Group Reshapes the Effects of Pyrido[3,4- · full record | OpenQuestion